Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging Study of Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 23-Year-Old Women.

Next Previous
X
Search
Trial Profile

A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging Study of Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 23-Year-Old Women.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Human papillomavirus vaccine recombinant octavalent Merck (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 19 Nov 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Aug 2008 Added official title, patient numbers and secondary identifier (V502-001) as reported by ClinicalTrials.gov.
    • 18 Dec 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top